Plain-English translation of NCT06909877 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new oral medication called HH2853 in patients with peripheral T-cell lymphoma that has come back or stopped responding to previous treatments. The study has two phases: first, researchers will figure out the safest and most effective dose of the medication, then test it in a larger group of patients to see how well it works. This medication works by targeting specific proteins that help cancer cells grow.
Peripheral T-cell lymphoma is a rare blood cancer that is often hard to treat, and many patients' cancers come back or stop responding to standard chemotherapy and newer drugs. This trial exists to find out whether this new treatment option can help patients whose cancer has become resistant to other therapies.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth twice daily at a dose that researchers will determine based on safety data from earlier participants. During the first phase, researchers will carefully monitor your safety and response to find the best dose. If that phase is successful, the second phase will enroll more patients to confirm how well the medication works. You will have regular visits for blood tests, physical exams, and imaging scans to track how your cancer is responding.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China